Conclusion? I feel like we're only just getting started. Everything up to this point was basically the pre-season. Now we know that Anavex is going to present its data and make its case for approval -- worst case the FDA says not yet, and Anavex can run the next trial without any shareholder dilution.
Besides, three years goes by fast in the grand scheme of things. Covid doesn't feel like that long ago. Time will pass. I'd rather wait three more years with a winning lotto ticket than wait 24 hours with a losing one. There's a 96% failure rate in Alzheimer's research. I don't think people appreciate what Anavex just accomplished with a successful trial.
News 
Market Data 
Discover 
